血管紧张素转换酶抑制剂对糖尿病肾病的保护作用  

Protection of ACEI on diabetic nephropathy

作　　者：陈继芳[1] 陈绪才[1] 

机构地区：[1]句容市人民医院,江苏省句容市212400

出　　处：《中国厂矿医学》2006年第6期490-491,共2页Chinese Medicine of Factory and Mine

摘　　要：目的探讨血管紧张素转换酶抑制剂洛汀新对早期糖尿病肾病的保护作用。方法选择经临床确诊的早期糖尿病肾病116例,随机分为2组:一组单纯控制血糖至理想水平,另一组在控制血糖的同时加用洛汀新10 mg/d,治疗1年。观察2组患者尿微量白蛋白的排泄情况。结果洛汀新治疗组患者尿微量白蛋白排泄较治疗前明显减少(P<0.01),而对照组无明显变化(P>0.20)。结论血管紧张素转换酶抑制剂洛汀新能明显减少尿微量白蛋白的排泄,对早期糖尿病肾病有保护作用。Objective To investigate the protective effects of Angiotensin - converting enzyme inhibitor （ACEI） on incipient diabetic nephropathy（DN）. Methods One hundred and sixteen clinical definite patients were divided into two groups, the experimental group were treated with Lotensin 5mg,qd,for one year,and the control group were treated merely to degrade the blood glucose concentration. The both groups were treated to ideal blood glucose concentration. The two groups＇urlnary albumin excretion were observed. Results Urinary albumin excretion of experimental group obviously decreased compared with the pretherapy level （P 〈 0. 01 ）, while the control group had no marked ehange（P 〉0. 20）. Conclusions ACEI can obviously decrease the urinary albumin in patients with incipient DN, and achieve the curative effect of the protection of renal function.

关 键 词：血管紧张索转换抑制剂 糖尿病肾病 尿白蛋白 

分 类 号：R587.2[医药卫生—内分泌]